Compare TCRX & EXYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCRX | EXYN |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.4M | 47.6M |
| IPO Year | 2021 | 2026 |
| Metric | TCRX | EXYN |
|---|---|---|
| Price | $0.75 | $3.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 311.4K | ★ 1.3M |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.28 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,325,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.81 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 266.65 | N/A |
| 52 Week Low | $0.72 | $1.50 |
| 52 Week High | $2.57 | $6.98 |
| Indicator | TCRX | EXYN |
|---|---|---|
| Relative Strength Index (RSI) | 41.36 | 56.40 |
| Support Level | $0.73 | $1.58 |
| Resistance Level | $0.82 | $6.90 |
| Average True Range (ATR) | 0.04 | 0.61 |
| MACD | 0.01 | 0.27 |
| Stochastic Oscillator | 9.48 | 75.09 |
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.